ARTICLE | Clinical News
Letermovir: Additional Ph III MK-8228-001 data
March 3, 2017 5:07 AM UTC
Additional data from the double-blind, international, Phase III MK-8228-001 trial in 495 CMV-seropositive recipients of HSCTs showed that letermovir for up to 14 weeks post-HSCT with or without cyclos...